SRPT News and Press, Sarepta Therapeutics Inc. From 12/11/25

2025-12-11 07:46:21 ET More on Sarepta Therapeutics Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026 FDA Duchenne Failure Hits Sarepta Amid 3Q25 Earnings Beat Sarepta Therapeutics, Inc. 2025 Q3 - Results - Earnings Call Presentation Sare...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has entered into separate, privately negotiated exchange agreements with a limited number of holders of its 1.25% convertible senior notes due 2027 (the “Existing C...

2025-12-09 11:03:20 ET More on Sarepta Therapeutics Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026 FDA Duchenne Failure Hits Sarepta Amid 3Q25 Earnings Beat Sarepta Therapeutics, Inc. 2025 Q3 - Results - Earnings Call Presentation Sare...

2025-11-27 07:20:44 ET Introduction As the year comes to an end, we must be thankful for the therapies that are in late clinical stages. Most importantly, patients are set to benefit immensely. But nearly every trial candidate has implications beyond just patients. The approval of a...

Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study, which is expected to begin before the end of the year The enhanced immunosuppressive regimen is designed to mitigate the risk of acute liver injury (ALI) and a...

2025-11-24 07:45:50 ET More on Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome Transcript Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and C...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1, also calle...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared progress in the Phase 1/2 multiple ascending dose (MAD) clinical study of SRP-1003 (formerly ARO-DM1), an investigational small interfering RNA (siRNA) therapeutic for the treatment ...

2025-11-17 10:08:12 ET Arrowhead Pharmaceuticals ( ARWR ) has a busy schedule in the next few weeks. The PDUFA date for plozasiran for the treatment of familiar chylomicronemia syndrome (‘FCS’) is tomorrow, fiscal Q4 2025 results are expected next week, and we shou...

2025-11-14 16:24:02 ET More on Sarepta Therapeutics Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026 FDA Duchenne Failure Hits Sarepta Amid 3Q25 Earnings Beat Sarepta Therapeutics, Inc. 2025 Q3 - Results - Earnings Call Presentation Sare...